{
    "title": "108_s2997",
    "content": "The \"Flu Vaccine Incentive Act of 2004\" or \"FLU-VIA\" eliminates the price cap for purchasing influenza vaccines. The \"Flu Vaccine Incentive Act of 2004\" removes price restrictions for purchasing influenza vaccines under the Vaccines for Children Program. The amendments made by the \"Flu Vaccine Incentive Act of 2004\" apply to contracts entered into after the enactment date. Additionally, the Act applies to the purchase of influenza vaccines by any Federal agency under agreements negotiated by the Secretary of Health and Human Services. Incentives for constructing influenza vaccine manufacturing facilities. Incentives for constructing influenza vaccine manufacturing facilities include the Influenza Vaccine Manufacturing Facilities Investment Tax Credit, which allows for a 20 percent credit on qualified investments for any taxable year. The Influenza Vaccine Manufacturing Facilities Investment Tax Credit provides a 20 percent credit on qualified investments for any taxable year. The qualified investment is the basis of each influenza vaccine manufacturing facilities property placed in service by the taxpayer during that year. This property includes real and tangible personal property used for manufacturing, distribution, or research and development of influenza. The Influenza Vaccine Manufacturing Facilities Investment Tax Credit offers a 20 percent credit on qualified investments for influenza vaccine manufacturing facilities property. The property must be in compliance with relevant regulations and standards. Certain progress expenditure rules apply, and the subsection does not apply to property placed in service after December 31, 2014. Technical amendments are also included. The Internal Revenue Code of 1986 has been amended to include the basis of influenza vaccine manufacturing facilities property for tax credits. Additionally, technical amendments have been made to certain sections of the Code. The Internal Revenue Code of 1986 has been amended to include tax credits for influenza vaccine manufacturing facilities. Additionally, technical amendments have been made to certain sections of the Code. The amendments apply to property placed in service after December 31, 2004. The Senate finds that only 2 companies produce the influenza vaccine in the US, grown in eggs taking 6 months. New technologies like using silk moth cell lines promise faster and cheaper production. It is prudent to allocate more funds for vaccine production. It is advisable to allocate more funds to the National Institutes of Health for research on new technologies for influenza vaccine production."
}